Objectives: Bronchiolitis is the most common disease of the lower respiratory tract in the first year of life. Treatment is controversial, with studies giving conflicting views on the benefits of bronchodilators and steroids. The objectives of this study were 1) to characterize the management of bronchiolitis in pediatric emergency departments (PEDs) in Canada, 2) to determine patient outcomes following emergency department (ED) visits, and 3) to provide descriptive data regarding bronchiolitis symptoms and family/personal medical history of these patients. Methods: A prospective consecutive cohort of children with bronchiolitis presenting to seven Canadian PEDs was enrolled during a seven-to-21-day period. Standardized interviews with parents provided data regarding symptoms, previous treatment, and past history. Charts were reviewed for treatment, investigations, and disposition. Telephone follow-up at two to three weeks collected information regarding duration of illness and return visits. Results: Two hundred thirty-seven (91%) of 260 eligible patients were enrolled. One hundred eighty-nine patients (80%) had both an interview and chart review, and 48 (20%) had only chart reviews; follow-up was completed for 163 (69%) patients. One hundred fifteen (63%) had seen their primary care provider during their illness prior to the ED visit. Seventythree percent of patients (range per site 59-100%) were treated in the ED with bronchodilators (usually salbutamol or epinephrine) and 5% (range per site 0-14%) with oral steroids. Twenty-four percent (58/237) were prescribed bronchodilators on discharge, 3% (7/237) inhaled steroids, and 2% (5/237) oral steroids. Chi-square tests indicated significant practice variation by site in ED bronchodilator use (p \ 0.001) and bronchodilator use at discharge (p = 0.0003). Admission rate was 31% (range by site 22-43%), 17% of patients had more than one ED visit, and 1% were admitted more than once. Admission rates were increased in younger children, children with comorbidities, and children with lower oxygen saturation. Viral studies were obtained in 53%, with 76% of these positive for respiratory syncytial virus (RSV). Median duration of cough was 12 days, poor sleeping and irritability eight days, and wheeze and poor feeding seven days. Conclusions: This study prospectively describes the treatment of bronchiolitis in the pediatric ED. The findings are consistent with the literature regarding the reported use of bronchodilators; however, use of steroids was found to be much lower than reported in other studies. Bronchodilator use in the ED and at discharge varied significantly by site. The results capture variation in treatment practices in Canadian PEDs, which may be the result of discordant randomized controlled trial evidence. Further research is needed to establish best practices.
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5 Current Canadian statistics demonstrate that 35 per 1,000 infants are admitted to the hospital with bronchiolitis. The annual cost of RSV bronchiolitis in Canada is conservatively estimated at 18 million U.S. dollars. 6 The current treatment of bronchiolitis is controversial. Published studies give conflicting views on the benefits of bronchodilators and steroids. Meta-analysis has failed to find any consistent benefit of bronchodilators (either beta-agonists or epinephrine) when inpatient and outpatient studies are combined. 7 However, in emergency department (ED) patients, bronchodilators may have some modest short-term benefit. [8] [9] [10] [11] [12] Although the majority of individual randomized controlled trials (RCTs) [13] [14] [15] [16] examining the use of steroids have shown no benefit, metaanalysis suggests that in admitted patients, steroids may provide a small improvement in length of stay. 17 One recent emergency-based study found a significant reduction in admission rates in those treated with high-dose steroids as compared with placebo. 18 Several cohort studies have examined the management and course of admitted patients. 19, 20 These studies have shown widespread use of bronchodilators (42-95% of patients), and some have also suggested that this varies considerably by site. [19] [20] [21] Studies that surveyed physicians regarding their inpatient and outpatient management of bronchiolitis also suggest widespread use of bronchodilators and of steroids. [22] [23] [24] [25] One study has been published describing the duration of illness in an outpatient cohort of patients with bronchiolitis. 26 To the best of our knowledge, no studies have been published that prospectively examine the management of bronchiolitis in the ED.
The objectives of this study were 1) to characterize the management of bronchiolitis in participating EDs in Canada, 2) to follow patient outcomes following an ED visit, and 3) to provide descriptive data regarding bronchiolitis symptoms and family/personal medical history of these patients.
METHODS
Study Design. This study was a prospective cohort study of consecutive children presenting to the ED with bronchiolitis. A standardized survey, chart review, and telephone follow-up were used to collect study information regarding eligible patients. The institutional review boards of all participating hospitals approved this study.
Study Setting and Population. This study was conducted in the ED of seven tertiary care children's hospitals over a one-to-three-week period during the winter of 2002. There are ten tertiary care children's hospitals in Canada; the seven study hospitals reflect a cross-country distribution, and all study hospitals are members of an emergency research collaborative group (Pediatric Emergency Research Canada). The EDs in this study have annual censuses ranging from 17,000 to 55,000. All patients #12 months of age presenting to the ED with bronchiolitis were eligible for the study. Bronchiolitis was defined as the first episode of wheezing in a child #12 months with associated signs of an upper respiratory tract infection (such as fever or coryza). Wheezing needed to be noted by the examining physician rather than by parental report.
Study Protocol. During the study period, research assistants were available to recruit patients in the ED either 24 hours a day (four centers) or eight hours a day (three centers). Parents of eligible patients were approached for consent for interview and/or chart review. A standardized survey, administered by study personnel, collected descriptive data from the parents regarding bronchiolitis symptoms, medical treatment sought during the child's illness, family/personal medical history, and home environment. Telephone follow-up using another standardized survey was completed at two to three weeks following the ED visit. This follow-up provided information regarding length of symptoms, subsequent visits to health care providers, and admissions to hospital. The standardized surveys consisted of a series of single-and multiple-select closed-ended items; however, these items also allowed for selection of a residual ''other'' category. In cases in which the respondent felt that his or her response did not correspond to those already listed (i.e., he or she selected ''other''), the respondent was asked to elaborate on his or her answer in full text. A review of the ED chart collected information regarding treatment given, investigations in the ED, length of stay, and child's disposition. A chart review at 21 days was also completed to confirm subsequent ED visits and hospitalizations at each study site. A daily review of ED census allowed determination of missed eligible patients. All research assistants received training regarding administration of the survey tools, chart review, and telephone follow-up.
Data Analysis. Data were entered in a Microsoft Access 2000 database (Microsoft Corp., Redmond, WA) and analyzed using S-PLUS 2000 (Insightful Corp., Seattle, WA). Overall descriptive statistics were used to describe patient characteristics, clinical signs and symptoms, treatment and management practices, and outcomes. In addition, specific institutional values were described for treatment and management practices and outcomes. Dichotomous variables were expressed as percentages with 95% confidence intervals (CIs); continuous variables were expressed as medians and interquartile ranges.
Chi-square tests were used to test for differences across sites in the use of bronchodilators in the ED and upon discharge, admissions, for viral studies, and chest radiographs. The expected cell count assumption suggested by Yarnold 27 Seven sites participated; three did not attain the minimum number of patients. However, total sample size was exceeded.
RESULTS
Sample Specifications. A total of 237 of 260 eligible patients (91%) were enrolled. One hundred eighty-nine children (80%) completed parental interviews and chart reviews, while 48 (20%) completed only chart reviews. Telephone follow-up, which was possible only for interviewed families, was completed for 163 subjects (69%). Sample size by institution ranged from 14 to 85. The median age of enrolled patients was 5 months (2-8 interquartile range), and 59% were male. Table 1 gives patient characteristics in detail. The majority (71%) had a family history of atopy and many (36%) came from home-smoking environments.
Preceding Symptoms and Treatments. Symptoms upon presentation to the PED included coughing (100%), nasal congestion (94%), wheezing audible to parents (89%), difficulty breathing (87%), poor feeding (70%), poor sleeping (69%), irritability (67%), fever (59%), vomiting (51%), and choking (41%). The earliest symptoms, nasal congestion and coughing, appeared on average (median) four days before presentation at the PED. Irritability occurred on average three days before, and the remaining symptoms occurred on average two days before. One hundred fifteen children (63%) had seen their primary care provider (PCP) during their illness prior to the PED visit. Forty-eight (44%) of these 115 patients had been prescribed medications by the PCP before the PED visit, namely, antibiotics (27) , oral salbutamol (9), orciprenaline (4), metered-dose inhaler (MDI) salbutamol (8), budesonide (3), oral steroids (2), MDI fluticasone (2), and nebulized salbutamol (1). Thirtyseven (32%) of the children who had seen their PCP had been diagnosed as having bronchiolitis.
ED Management. Table 2 gives the treatment and management practice variation in the use of bronchodilators, and steroids across participating institutions, while Figure 1 shows the use epinephrine and 
*Data regarding smoking in the home and respiratory syncytial virus (RSV) immunoglobulin were collected at only three hospitals, n = 83 possible. yTwo hundred thirty-seven patients had chart reviews completed but two were missing responses to this question. Figure 1 ) showed a statistically significant preference for salbutamol over epinephrine (p # 0.02); one site showed a preference for epinephrine (p \ 0.0001).
The association between several clinical variables (i.e., respiratory rate, oxygen saturation, comorbidity, age, gender, personal history of atopy, family history of atopy, and parental smoking) and bronchodilator use was investigated in logistic regression; all clinical variables were insignificant. There was also no difference specifically in the use of bronchodilators among patients with and without a family history of asthma (p = 0.77). Twenty-four percent of children were sent home with bronchodilators. One institution sent 79% of patients home on bronchodilators. The remaining centers sent less than (or equal to) 30% of patients home with bronchodilators. The chi-square test found at least one significant difference in percentages across sites (p = 0.0003). Of those children discharged on bronchodilators, 88% were sent home with salbutamol by MDI, 10% were sent home with nebulized salbutamol, and one was sent home with orciprenaline.
Few children (5% or a total of 12) were treated with steroids in the PED. This number ranged from 0% to 14% for the various institutions; this was not statistically significant (p = 0.27). Of those treated with steroids in the PED, nine were treated with oral steroids and three with nebulized steroids. Ten children (4%) were sent home with steroid medication; two on both oral and inhaled steroids, three on oral steroids, and five on inhaled steroids. Twenty-one children (9%) were discharged on antibiotics; one of these had been previously prescribed antibiotics.
Investigations in the ED. Overall, 124 children (53%) had viral studies done, 94 (76%) of which were positive for RSV. Viral testing varied significantly among sites (p \ 0.0001) with a range of 31-92% of patients receiving viral studies. Viral testing was not solely related to cohorting for admission, as 54% of patients receiving viral testing were discharged home. Ninety-nine (42%) had chest radiographs taken, and again this varied significantly among sites (p = 0.0004) with a range of 18-68%. Blood work was taken in 35 (15%) of patients, with the most common test being a complete blood count.
Patient Outcomes. Admissions to hospital and return visits to the PED are recorded in Table 3 and Figure 2 . Overall, 31% of PED patients were admitted to the hospital with bronchiolitis at least once, and three children were admitted more than once. Of the admitted patients, 84% were admitted at their initial visit and 16% were admitted at a subsequent visit. By institution, this number ranged from 22% to 46%; this variation was not significant (p = 0.68). Seventeen percent of patients (range 4-35%) had a return visit to the ED; this was statistically significant (p = 0.01).
Admission was associated with age, comorbidity, and pulse oximetry. For every one month decrease in age, the odds of admission was increased by 1.3 (odds ratio 95% CI = 1.2 to 1.5). Presence of comorbidities increased the odds of admission by 3.9 (95% CI = 1.5 to 10.0). For every 1% reduction in pulse oximetry, the odds increased by 1.3 (95% CI = 1.1 to 1.4). Gender, personal and family histories of atopy, and parental smoking were not associated with admission, and the respiratory rate dropped out of the model when adjusted for pulse oximetry.
One hundred sixty-three patients agreed to the follow-up telephone interview. One hundred eleven had visited their primary care provider in the two weeks following their PED visit: 74% for routine check-up, 26% worsening symptoms (Table 3) , 3% concerned about misdiagnosis, and 4% for other reasons. Symptom duration is shown in Table 4 . Approximately two weeks after the initial PED visit, 160 children felt much better (88%) or a little better (10%). Only one child was reported as not improving, and one child's condition worsened.
DISCUSSION
To the best of our knowledge, our study is the first to describe prospectively the treatment of bronchiolitis in the pediatric ED. We found that the majority of children with bronchiolitis presenting to a pediatric ED are treated with bronchodilators but that there is significant site-to-site variation in the frequency of bronchodilator use and in the type of bronchodilator used. This result (73% of patients received at least one bronchodilator treatment) is similar to that found in inpatient studies, as well as several survey studies that have suggested usage ranging from 42% to 90%. 19, 20, 24, 30 Other studies have demonstrated siteto-site variation in the management of inpatients with bronchiolitis. 21, 30 We found our use of epinephrine (58%) to be significantly higher than previously reported in the literature. Specifically, in the one recent American study that surveyed emergency physicians regarding their management of bronchiolitis, only 13% of physicians reported they would use nebulized epinephrine. 25 We did not find a high use of anticholinergic agents, as has been reported in other studies. 30 The variation in bronchodilator use observed in this study likely reflects the influence of the many small and conflicting RCTs in this area, [8] [9] [10] 12, [31] [32] [33] [34] [35] the evidence that they may be beneficial for outpatients but not for inpatients and possibly the frustration of clinicians attempting to treat this illness. The high use of epinephrine may reflect the influence of previous RCTs demonstrating efficacy of epinephrine completed at two of our study hospitals.
9,31 Also of note, many patients were discharged home on inhaled bronchodilators, although no studies have been published examining their use and no study has previously documented the extent of their use. It is reassuring to see that oral bronchodilators (such as orciprenaline and liquid salbutamol) were seldom or never prescribed since studies have demonstrated that they have no benefit. 32, 34 Despite the variation in ED treatment and outpatient medications found in our study, no corresponding variation in admission rate was detected. This may be due to other variables predicting admission not related to treatment, or perhaps treatments are not effective in reducing admission rates. Furthermore, since all participating hospitals were children's hospitals that provide both primary and tertiary care, we have no reason to believe that the patient populations were significantly different in severity of illness.
Interestingly, unlike most published studies, the use of steroids both acutely and upon discharge was extremely small in our population. Inpatient studies have suggested usage of 36-80%. 21, 24, 36 However, studies that survey emergency physicians regarding their treatment of bronchiolitis report steroids are prescribed by pediatric emergency physicians of 45% in 1994 and only 7% in 2000. 23, 25 Since there is little evidence that steroids are beneficial in treating bronchiolitis, the low use of steroids in our study appears to be evidence-based. This is also the first study to systematically describe the family history of a cohort of ambulatory patients with bronchiolitis. We found a family history of atopy in 71% of our patients, with 43% having a family history of asthma specifically. We found that cough was the longest symptom reported by families, lasting a median of 12 days (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . This is similar to an earlier study's findings, in which parents reported children being ill (with any symptom) for a median of 12 days. 26 Our study indicates that bronchiolitis puts a significant burden of disease on the family and patient and in turn must have significant health care costs. Apart from the numerous medications with which these patients are treated (both in the PED and by their family physician), many also had viral studies and chest radiographs obtained in the ED. These investigations increase health care costs and potentially add little in managing this illness. Several studies have been published that examine the effects of implementing clinical guidelines on the management of bronchiolitis. Those studies that have assessed the implementation of a guideline within a specific hospital have shown reduction in use of beta-agonist therapy, radiographs, and viral testing, [37] [38] [39] and for some, a reduction in length of stay. 37, 38 
LIMITATIONS
The short sampling time frame of our study and resultant small numbers is a limitation to our study, although we had close to complete capture of all eligible patients. This would suggest there is likely no systematic bias to the study and our results capture treatment practices in Canadian PEDs. The short sampling time frame may also have resulted in missing some of the seasonal variation in bronchiolitis presentation and possibly physician management. The use of several interviewers/chart reviewers was necessary to cover all sites and may have resulted in some interview bias despite the use of a standardized interview tool. Data regarding investigations and treatments, however, were obtained by chart review during the child's stay in the PED on a standardized data collection form. Interobserver reliability on the information extracted from chart review was not performed. Since telephone follow-up was only at two to three weeks following the patients visit to the PED, the length of symptoms reported may not be precise. 
